Remicade: A Study In Translational Looping
This article was originally published in Pharmaceutical Approvals Monthly
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
You may also be interested in...
Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.